SenAI Intelligence Receives China's First Medical Device Registration Certificate for VTE Risk Assessment Software

Recently, SYNYI·AI’s flagship product, the “Venous Thromboembolism Risk Assessment Software,” has obtained the medical device registration certificate for venous thromboembolism (VTE) risk assessment software.

“AI + Healthcare” is one of the key application scenarios for the implementation of artificial intelligence technologies. As the industry enters a phase of market value validation, this multi-billion-dollar market (Source: IDC China’s First Half 2021 Artificial Intelligence Market Share Report) is facing a new inflection point. Moving beyond concepts and narratives, how AI technology can truly “integrate” into healthcare scenarios to empower the industry and break through commercialization bottlenecks has become critical to enterprise development.

SYNYI·AI’s Venous Thromboembolism Risk Assessment Software, which has recently received regulatory approval, is primarily designed to assist healthcare professionals in automatically evaluating patients’ risk of developing Venous Thromboembolism (VTE) during their clinical visits.

VTE is a fatal cardiovascular disease. Patients in many clinical departments are at risk of VTE. Its onset is insidious, and its clinical symptoms are atypical, making it prone to misdiagnosis and missed diagnosis. Once it occurs, the rates of mortality and disability are high.

VTE, as a cross-disciplinary disease, poses significant challenges to hospital management. A key contributing factor is that most hospitals currently rely on manual risk assessment, which is time-consuming, labor-intensive, and prone to delays. Therefore, there is an urgent need for hospitals to leverage emerging technologies to enhance the efficiency and effectiveness of VTE risk management.

SYNYI·AI’s Venous Thromboembolism Risk Assessment Software, which has recently received regulatory approval, is primarily designed to assist healthcare professionals in automatically evaluating patients’ risk of developing VTE during their hospital visits. The software enhances the accuracy and timeliness of VTE risk assessments, reduces the time required for evaluation, facilitates early identification of patients at risk for VTE, and plays a positive role in hospital-based VTE risk management.

As a national high-tech enterprise, SYNYI·AI has always adhered to the dual focus on product research and development and clinical application implementation. During the critical period of China’s 14th Five-Year Plan, the company continues to drive high-quality technological innovation.

Since its establishment in 2016, this young medical AI enterprise has not only achieved rapid growth but also actively committed to promoting high-quality innovation and standardization across the industry. SYNYI·AI has participated in the drafting of multiple industry standards and related research projects, and has been actively involved in the construction of key regional initiatives, taking concrete actions to accelerate the medical industry’s transition onto a “fast track” of standardized and secure development.

“For our company, this ‘weighty’ registration certificate proves that our products have truly integrated AI technology with clinical needs, earning recognition from hospitals and the industry,” said Ma Handong, co-founder of SYNYI·AI.

Dr. Zhang Shaodian, Founder and CEO of SYNYI·AI, stated, “The approval of the medical device registration certificate for our VTE software marks SYNYI·AI’s comprehensive launch of a multi-dimensional development strategy that integrates healthcare informatization, data intelligence, and innovative medical device commercialization, all grounded in AI and big data technologies.”

This aligns perfectly with SYNYI·AI’s corporate vision: “Leader in Intelligent Healthcare, Guardian of Billions of Lives.” By truly integrating artificial intelligence into healthcare scenarios, it empowers the high-quality development of public hospitals and safeguards the health of the people.